While Terns Pharmaceuticals Inc has overperformed by 6.56%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TERN rose by 406.14%, with highs and lows ranging from $28.49 to $1.87, whereas the simple moving average jumped by 342.65% in the last 200 days.
On November 04, 2025, H.C. Wainwright Upgraded Terns Pharmaceuticals Inc (NASDAQ: TERN) to Buy. A report published by William Blair on November 03, 2025, Upgraded its rating to ‘Outperform’ for TERN. Truist also rated TERN shares as ‘Buy’, setting a target price of $20 on the company’s shares in an initiating report dated October 15, 2025. Barclays Initiated an Overweight rating on September 17, 2025, and assigned a price target of $15. H.C. Wainwright initiated its ‘Neutral’ rating for TERN, as published in its report on September 04, 2025. Oppenheimer also rated the stock as ‘Outperform’.
Analysis of Terns Pharmaceuticals Inc (TERN)
To gain a thorough understanding of Terns Pharmaceuticals Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -29.12% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.52, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and TERN is recording an average volume of 2.54M. On a monthly basis, the volatility of the stock is set at 10.32%, whereas on a weekly basis, it is put at 7.82%, with a gain of 9.70% over the past seven days. Furthermore, long-term investors anticipate a median target price of $28.70, showing growth from the present price of $28.04, which can serve as yet another indication of whether TERN is worth investing in or should be passed over.
How Do You Analyze Terns Pharmaceuticals Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 15.96%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 81.68% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
